{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:18:42Z","timestamp":1788578322157,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.xphs.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:16:45Z","timestamp":1537402605000},"page":"798-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule"],"prefix":"10.1016","volume":"108","author":[{"given":"Jane P.F.","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xphs.2018.09.010_bib2","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/cdd.2015.67","article-title":"Molecular mechanisms of Ebola virus pathogenesis: focus on cell death","volume":"22","author":"Falasca","year":"2015","journal-title":"Cell Death Differ"},{"issue":"11","key":"10.1016\/j.xphs.2018.09.010_bib3","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.3390\/v6114760","article-title":"Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014","volume":"6","author":"Kuhn","year":"2014","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.xphs.2018.09.010_bib4","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.cell.2015.06.007","article-title":"Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone","volume":"161","author":"Park","year":"2015","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.xphs.2018.09.010_bib5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A\u00a0randomized, controlled trial of ZMapp for ebola virus infection","volume":"375","author":"Davey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.xphs.2018.09.010_bib8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrmicro3524","article-title":"Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus","volume":"13","author":"Messaoudi","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.xphs.2018.09.010_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.micinf.2014.11.012","article-title":"Development of therapeutics for treatment of Ebola virus infection","volume":"17","author":"Li","year":"2015","journal-title":"Microbes Infect"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.010_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40588-015-0021-3","article-title":"Ebola virus entry into host cells: identifying therapeutic strategies","volume":"2","author":"Rhein","year":"2015","journal-title":"Curr Clin Microbiol Rep"},{"issue":"10","key":"10.1016\/j.xphs.2018.09.010_bib11","doi-asserted-by":"crossref","first-page":"e0005996","DOI":"10.1371\/journal.pntd.0005996","article-title":"Characterization of the catalytic center of the Ebola virus L polymerase","volume":"11","author":"Schmidt","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"7364","key":"10.1016\/j.xphs.2018.09.010_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"Carette","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.010_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40506-017-0130-z","article-title":"Discovering drugs for the treatment of ebola virus","volume":"9","author":"Bixler","year":"2017","journal-title":"Curr Treat Options Infect Dis"},{"issue":"17","key":"10.1016\/j.xphs.2018.09.010_bib14","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1128\/JVI.01410-14","article-title":"Ebola virus modulates transforming growth factor beta signaling and cellular markers of mesenchyme-like transition in hepatocytes","volume":"88","author":"Kindrachuk","year":"2014","journal-title":"J\u00a0Virol"},{"issue":"10","key":"10.1016\/j.xphs.2018.09.010_bib16","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/j.xphs.2016.07.004","article-title":"Pharmacodynamics and systems pharmacology approaches to repurposing drugs in the wake of global health burden","volume":"105","author":"Bai","year":"2016","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.010_bib18","doi-asserted-by":"crossref","first-page":"e0004364","DOI":"10.1371\/journal.pntd.0004364","article-title":"A\u00a0rapid screening assay identifies monotherapy with interferon-ss and combination therapies with nucleoside analogs as effective inhibitors of ebola virus","volume":"10","author":"McCarthy","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.010_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3201\/eid2103.141862","article-title":"Lack of effect of lamivudine on Ebola virus replication","volume":"21","author":"Hensley","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.xphs.2018.09.010_bib20","doi-asserted-by":"crossref","first-page":"e0166318","DOI":"10.1371\/journal.pone.0166318","article-title":"Evaluation of the activity of lamivudine and zidovudine against ebola virus","volume":"11","author":"Cong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.xphs.2018.09.010_bib21","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1086\/520597","article-title":"Analysis of filovirus entry into Vero E6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity","volume":"196","author":"Sanchez","year":"2007","journal-title":"J\u00a0Infect Dis"},{"issue":"190","key":"10.1016\/j.xphs.2018.09.010_bib22","doi-asserted-by":"crossref","first-page":"190ra179","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.xphs.2018.09.010_bib23","doi-asserted-by":"crossref","first-page":"e60579","DOI":"10.1371\/journal.pone.0060579","article-title":"A\u00a0systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.xphs.2018.09.010_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect Dis"},{"issue":"8","key":"10.1016\/j.xphs.2018.09.010_bib25","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1021\/acsinfecdis.5b00053","article-title":"High-throughput minigenome system for identifying small-molecule inhibitors of ebola virus replication","volume":"1","author":"Edwards","year":"2015","journal-title":"ACS Infect Dis"},{"issue":"290","key":"10.1016\/j.xphs.2018.09.010_bib26","doi-asserted-by":"crossref","first-page":"290ra289","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A\u00a0screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xphs.2018.09.010_bib27","doi-asserted-by":"crossref","first-page":"13476","DOI":"10.1038\/srep13476","article-title":"Identification of agents effective against multiple toxins and viruses by host-oriented cell targeting","volume":"5","author":"Zilbermintz","year":"2015","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.xphs.2018.09.010_bib28","first-page":"e84","article-title":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs","volume":"3","author":"Kouznetsova","year":"2014","journal-title":"Emerg Microbes Infect"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2018.09.010_bib29","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1086\/514313","article-title":"ELISA for the detection of antibodies to Ebola viruses","volume":"179","author":"Ksiazek","year":"1999","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.010_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.virol.2004.10.048","article-title":"Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening","volume":"332","author":"Towner","year":"2005","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.010_bib31","doi-asserted-by":"crossref","first-page":"26.12.1","DOI":"10.1002\/0471143030.cb2612s51","article-title":"An enzymatic assay for detection of viral entry","volume":"51","author":"Tscherne","year":"2011","journal-title":"Curr Protoc Cell Biol"},{"issue":"12","key":"10.1016\/j.xphs.2018.09.010_bib32","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1099\/jgv.0.000309","article-title":"Chloroquine inhibited Ebola virus replication in\u00a0vitro but failed to protect against infection and disease in the in\u00a0vivo Guinea pig model","volume":"96","author":"Dowall","year":"2015","journal-title":"J\u00a0Gen Virol"},{"issue":"6","key":"10.1016\/j.xphs.2018.09.010_bib33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3201\/eid2106.150176","article-title":"Lack of protection against ebola virus from chloroquine in mice and hamsters","volume":"21","author":"Falzarano","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"10.1016\/j.xphs.2018.09.010_bib34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMoa1504874","article-title":"Clinical management of ebola virus disease in the United States and Europe","volume":"374","author":"Uyeki","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2018.09.010_bib35","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.xphs.2018.09.010_bib36","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.010_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504605","article-title":"Effect of artesunate-amodiaquine on mortality related to ebola virus disease","volume":"374","author":"Gignoux","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.xphs.2018.09.010_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"6","key":"10.1016\/j.xphs.2018.09.010_bib39","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1128\/AAC.15.6.747","article-title":"Mechanism and specificity of action of ribavirin","volume":"15","author":"Browne","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"issue":"17","key":"10.1016\/j.xphs.2018.09.010_bib40","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.010_bib41","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.virol.2010.02.015","article-title":"Ebola virus uses clathrin-mediated endocytosis as an entry pathway","volume":"401","author":"Bhattacharyya","year":"2010","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.xphs.2018.09.010_bib42","doi-asserted-by":"crossref","first-page":"e00293","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"10.1016\/j.xphs.2018.09.010_bib43","doi-asserted-by":"crossref","first-page":"e56265","DOI":"10.1371\/journal.pone.0056265","article-title":"Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection","volume":"8","author":"Shoemaker","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.xphs.2018.09.010_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/femspd\/ftv032","article-title":"Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process","volume":"73","author":"Salata","year":"2015","journal-title":"Pathog Dis"},{"issue":"8","key":"10.1016\/j.xphs.2018.09.010_bib45","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1093\/jac\/dku091","article-title":"The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry","volume":"69","author":"Gehring","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.xphs.2018.09.010_bib46","first-page":"2212","article-title":"Mechanism of inhibition of cell proliferation by Vinca alkaloids","volume":"51","author":"Jordan","year":"1991","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.xphs.2018.09.010_bib47","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1021\/pr500556d","article-title":"Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host-cell protein function","volume":"13","author":"Garcia-Dorival","year":"2014","journal-title":"J\u00a0Proteome Res"},{"issue":"2","key":"10.1016\/j.xphs.2018.09.010_bib48","doi-asserted-by":"crossref","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"10.1016\/j.xphs.2018.09.010_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"Mentre","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.xphs.2018.09.010_bib51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cpt.172","article-title":"The Animal Rule: the role of clinical pharmacology in determining an effective dose in humans","volume":"98","author":"Bergman","year":"2015","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354918305379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:25:38Z","timestamp":1758360338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354918305379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0022354918305379"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2018.09.010","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}